Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (71)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Shibutani, S.
Right arrow Articles by Pearl, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shibutani, S.
Right arrow Articles by Pearl, M. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 21, No. 8, 1461-1467, August 2000
© 2000 Oxford University Press

Accelerated Paper

Identification of tamoxifen–DNA adducts in the endometrium of women treated with tamoxifen

Shinya Shibutani3, Anisetti Ravindernath, Naomi Suzuki, Isamu Terashima, Steven M. Sugarman1, Arthur P. Grollman and Michael L. Pearl2

Laboratory of Chemical Biology, Department of Pharmacological Sciences,
1 Division of Oncology and
2 Division of Obstetrics and Gynecology, School of Medicine, State University of New York at Stony Brook, Stony Brook, NY 11794, USA

The risk of developing endometrial cancer increases significantly for women treated with tamoxifen (TAM); the present study was designed to investigate the mechanism of this carcinogenic effect. Endometrial tissue was obtained from 16 women treated for varying lengths of time with TAM and from 15 untreated control subjects. DNA was analyzed with a 32P-post-labeling/HPLC on-line monitoring assay capable of detecting 2.5 adducts/1010 nucleotides. Using this sensitive and specific assay, TAM–DNA adducts were detected in eight women. The major adducts found were trans and cis epimers of {alpha}-(N2-deoxyguanosinyl) tamoxifen (dG-N2-TAM); levels ranged between 0.2–12 and 1.6–8.3 adducts/108 nucleotides, respectively. There was marked inter-individual variation in the relative amounts of cis and trans adducts present. Low levels (0.74–1.1 adducts/108 nucleotides) of trans and cis forms of dG-N2-TAM N-oxide were detected in one patient. DNA adducts derived from 4-hydroxytamoxifen quinone methide were not observed. We conclude from this analysis that trans and cis dG-N2-TAMs accumulate in significant amounts in the endometrium of many, but not all, women treated with this drug. The level of adducts found, coupled with the previous demonstration of their mutagenicity [Cancer Res., 59, 2091, 1999], suggest that a genotoxic mechanism may be responsible for TAM-induced endometrial cancer.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 MutagenesisHome page
K. Brown
Is tamoxifen a genotoxic carcinogen in women?
Mutagenesis, September 1, 2009; 24(5): 391 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. J. Schild-Hay, T. A. Leil, R. L. Divi, O. A. Olivero, A. Weston, and M. C. Poirier
Tamoxifen Induces Expression of Immune Response-Related Genes in Cultured Normal Human Mammary Epithelial Cells
Cancer Res., February 1, 2009; 69(3): 1150 - 1155.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Z. Qin, I. Kastrati, R. T. Ashgodom, D. D. Lantvit, C. R. Overk, Y. Choi, R. B. van Breemen, J. L. Bolton, and G. R. J. Thatcher
Structural Modulation of Oxidative Metabolism in Design of Improved Benzothiophene Selective Estrogen Receptor Modulators
Drug Metab. Dispos., January 1, 2009; 37(1): 161 - 169.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
E. Liapis, K. I.E. McLuckie, P. D. Lewis, P. B. Farmer, and K. Brown
Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots
Nucleic Acids Res., October 1, 2008; 36(18): 5933 - 5945.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
W. Chu, A. Fyles, E. M. Sellers, D. R. McCready, J. Murphy, T. Pal, and S. A. Narod
Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use
Carcinogenesis, October 1, 2007; 28(10): 2139 - 2142.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Brown, E. M. Tompkins, D. J. Boocock, E. A. Martin, P. B. Farmer, K. W. Turteltaub, E. Ubick, D. Hemingway, E. Horner-Glister, and I. N.H. White
Tamoxifen Forms DNA Adducts in Human Colon after Administration of a Single [14C]-Labeled Therapeutic Dose
Cancer Res., July 15, 2007; 67(14): 6995 - 7002.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Vivacqua, D. Bonofiglio, A. G. Recchia, A. M. Musti, D. Picard, S. Ando, and M. Maggiolini
The G Protein-Coupled Receptor GPR30 Mediates the Proliferative Effects Induced by 17{beta}-Estradiol and Hydroxytamoxifen in Endometrial Cancer Cells
Mol. Endocrinol., March 1, 2006; 20(3): 631 - 646.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Y. Kim, N. Suzuki, Y. R. S. Laxmi, and S. Shibutani
INEFFICIENT REPAIR OF TAMOXIFEN-DNA ADDUCTS IN RATS AND MICE
Drug Metab. Dispos., February 1, 2006; 34(2): 311 - 317.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Y. Kim, Y. R. S. Laxmi, N. Suzuki, K. Ogura, T. Watabe, M. W. Duffel, and S. Shibutani
FORMATION OF TAMOXIFEN-DNA ADDUCTS VIA O-SULFONATION, NOT O-ACETYLATION, OF {alpha}-HYDROXYTAMOXIFEN IN RAT AND HUMAN LIVERS
Drug Metab. Dispos., November 1, 2005; 33(11): 1673 - 1678.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
P. Parte and D. Kupfer
OXIDATION OF TAMOXIFEN BY HUMAN FLAVIN-CONTAINING MONOOXYGENASE (FMO) 1 AND FMO3 TO TAMOXIFEN-N-OXIDE AND ITS NOVEL REDUCTION BACK TO TAMOXIFEN BY HUMAN CYTOCHROMES P450 AND HEMOGLOBIN
Drug Metab. Dispos., October 1, 2005; 33(10): 1446 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
D. H. Phillips, A. Hewer, M. R. Osborne, K. J. Cole, C. Churchill, and V. M. Arlt
Organ specificity of DNA adduct formation by tamoxifen and {alpha}-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment
Mutagenesis, July 1, 2005; 20(4): 297 - 303.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
L. J. Schild, D. H. Phillips, M. R. Osborne, A. Hewer, F. A. Beland, M. I. Churchwell, K. Brown, M. Gaskell, E. Wright, and M. C. Poirier
Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods
Mutagenesis, March 1, 2005; 20(2): 115 - 124.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
International Breast Cancer Study Group
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93
Ann. Onc., December 1, 2004; 15(12): 1749 - 1759.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. A. Beland, M. I. Churchwell, D. R. Doerge, D. R. Parkin, D. Malejka-Giganti, A. Hewer, D. H. Phillips, P. L. Carmichael, G. Gamboa da Costa, and M. M. Marques
Electrospray Ionization-Tandem Mass Spectrometry and 32P-Postlabeling Analyses of Tamoxifen-DNA Adducts in Humans
J Natl Cancer Inst, July 21, 2004; 96(14): 1099 - 1104.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. J. Schild, R. L. Divi, F. A. Beland, M. I. Churchwell, D. R. Doerge, G. Gamboa da Costa, M. M. Marques, and M. C. Poirier
Formation of Tamoxifen-DNA Adducts in Multiple Organs of Adult Female Cynomolgus Monkeys Dosed with Tamoxifen for 30 Days
Cancer Res., September 15, 2003; 63(18): 5999 - 6003.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Shibutani, N. Suzuki, Y. R. S. Laxmi, L. J. Schild, R. L. Divi, A. P. Grollman, and M. C. Poirier
Identification of Tamoxifen-DNA Adducts in Monkeys Treated with Tamoxifen
Cancer Res., August 1, 2003; 63(15): 4402 - 4406.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
M. C. Poirier and L. J. Schild
The Genotoxicity of Tamoxifen: Extent and Consequences, Kona, Hawaii, January 23, 2003
Mutagenesis, July 1, 2003; 18(4): 395 - 399.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Yadollahi-Farsani, D. S. Davies, and A. R. Boobis
The mutational signature of {alpha}-hydroxytamoxifen at Hprt locus in Chinese hamster cells
Carcinogenesis, November 1, 2002; 23(11): 1947 - 1952.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Sridar, U. M. Kent, L. M. Notley, E. M. J. Gillam, and P. F. Hollenberg
Effect of Tamoxifen on the Enzymatic Activity of Human Cytochrome CYP2B6
J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. M. Klinge, S. C. Jernigan, and K. E. Risinger
The Agonist Activity of Tamoxifen Is Inhibited by the Short Heterodimer Partner Orphan Nuclear Receptor in Human Endometrial Cancer Cells
Endocrinology, March 1, 2002; 143(3): 853 - 867.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. Gamboa da Costa, L.P. McDaniel-Hamilton, R. H. Heflich, M.M. Marques, and F. A. Beland
DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives
Carcinogenesis, August 1, 2001; 22(8): 1307 - 1315.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. H. Phillips
Understanding the genotoxicity of tamoxifen?
Carcinogenesis, June 1, 2001; 22(6): 839 - 849.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Shibutani, A. Ravindernath, I. Terashima, N. Suzuki, Y. R. Santosh Laxmi, Y. Kanno, M. Suzuki, T. I. Apak, J. J. Sheng, and M. W. Duffel
Mechanism of Lower Genotoxicity of Toremifene Compared with Tamoxifen
Cancer Res., May 1, 2001; 61(10): 3925 - 3931.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.